The availability of a new oral weight-loss medication, Wegovy, in the UK marks a significant development in the field of obesity treatment, providing an alternative to weekly injections. For many, the prospect of a daily pill is seen as a more accessible and less daunting option than self-administered injections.
Lucy Cavendish, an early recipient of the Wegovy pill, described the anticipation surrounding its arrival, with pharmacies enthusiastically communicating its availability. Cavendish had been using the Mounjaro injection for approximately two years, during which she experienced substantial weight loss, dropping from 14st 3lb to 10st 3lb, and a dress size from 16 to 10. This transformation led to increased confidence, improved physical flexibility, and a general enhancement of her lifestyle.
GLP-1 medications like Wegovy and Mounjaro function by promoting a feeling of fullness, thereby reducing hunger. While injections like Mounjaro have been shown to result in an average weight loss of about 21% of body weight, the pill form of Wegovy is reported to achieve around 15%. However, for individuals focused on maintaining weight rather than losing more, the pill's efficacy in preventing weight regain is a key consideration.
Physiologically, GLP-1s work by mimicking hormones that signal satiety to the brain. The development of an oral form, which includes an absorption enhancer to protect the peptide semaglutide from stomach acid, represents a significant pharmaceutical advancement. This innovation addresses the challenges of delivering such medications orally, a hurdle that previously confined them to injectable formats.
The convenience factor is a major draw for oral weight-loss medications. Unlike the injectable pens, which require refrigeration and specific preparation with sterile swabs, pills are perceived as more familiar and easier to manage. Surveys indicate a significant portion of the public hesitant about injectable treatments would consider medication if offered in pill form.
Despite the perceived advantages, early user experiences with the Wegovy pill highlight potential drawbacks. Cavendish noted that taking the pill requires adherence to specific timing protocols: it must be taken on an empty stomach, with no food or drink for at least 30 minutes afterward, preferably an hour. This regimen can be inconvenient, particularly when managing morning routines.
Furthermore, some users have reported side effects similar to those experienced with injections, including digestive issues and fatigue. Cavendish experienced stomach pain and nausea after a few days of taking the pill, a contrast to her experience with Mounjaro, where she reported no side effects. Perhaps more concerning for some is the potential return of 'food noise' – the persistent cravings and thoughts about food that GLP-1s are designed to suppress. Cavendish reported experiencing hunger and cravings while on the pill, including a notable instance of consuming a hamburger and chips, which she had not experienced since before starting Mounjaro injections. This return of food noise raises concerns about long-term weight maintenance.
Eli Lilly's daily pill, Foundayo (orforglipron), is also expected to enter the UK market later this year, offering another oral option with a different administration profile, reportedly allowing for consumption with food and at any time of day, though potentially with slightly less efficacy than Wegovy in trials.
The weight-loss drug industry is projected to reach up to £150 billion by 2030, underscoring the significant market and demand for these treatments. However, as Cavendish's initial experience suggests, the transition to an oral format may involve trade-offs in effectiveness and management for some individuals, prompting a re-evaluation of treatment choices based on personal response and priorities. She indicated that if the pill does not effectively manage the 'food noise,' she would consider returning to injectable treatments.